Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 4/2001

01-10-2001

Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab)

Authors: Shinobu Umemura, Goi Sakamoto, Hironobu Sasano, Hitoshi Tsuda, Futoshi Akiyama, Masafumi Kurosumi, Yutaka Tokuda, Toru Watanabe, Masakazu Toi, Tadashi Hasegawa, R. Yoshiyuki Osamura

Published in: Breast Cancer | Issue 4/2001

Login to get access
Metadata
Title
Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab)
Authors
Shinobu Umemura
Goi Sakamoto
Hironobu Sasano
Hitoshi Tsuda
Futoshi Akiyama
Masafumi Kurosumi
Yutaka Tokuda
Toru Watanabe
Masakazu Toi
Tadashi Hasegawa
R. Yoshiyuki Osamura
Publication date
01-10-2001
Publisher
Springer-Verlag
Published in
Breast Cancer / Issue 4/2001
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/BF02967531

Other articles of this Issue 4/2001

Breast Cancer 4/2001 Go to the issue

OriginalPaper

New strategies for the treatment of breast cancer

OriginalPaper

E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations ofE1A gene therapy

OriginalPaper

International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland

OriginalPaper

The worldwide perspective in the adjuvant treatment of primary lymph node positive breast cancer

OriginalPaper

Treatment selection in ductal carcinomain situ

OriginalPaper

Third-generation aromatase inhibitors in the treatment of advanced breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits